Dose translation from animal to human studies revisited
[Adobe Stock] A flurry of recent FDA announcements and legal maneuvers has placed two popular weight-loss drugs tirzepatide (marketed as Mounjaro and Zepbound by Eli Lilly) and semaglutide (marketed as Ozempic and Wegovy by Novo Nordisk) at the center of a growing squabble
$249 $334* Formula : B-12 MIC $60 Being overweight or obese is one of the greatest threats to our health and increases our risk of heart disease, diabetes, high blood pressure, high cholesterol, stroke, cancer, depression, arthritis and joint pain, and sleep disorders, among other medical conditions
If side effects are significant, stay at the current dose for an additional four weeks before reconsidering
It delivers lasting results and significantly lowers the risk of life-threatening complications, making it a more reliable choice for achieving long-term health improvements
Peptides show promise, but they're not FDA-approved treatments